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Key Clinical Message
This article reports a rare but potentially serious complication of ductus arte-
riosus closure resulting from second-trimester indomethacin exposure. Serial
echocardiograms are indicated to monitor for development of right heart dys-
function and to ensure delivery prior to the onset of right heart failure and
hydrops fetalis.
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Case Report
A 34-year-old, gravid two, para zero woman was referred
to our center for fetal echocardiography at 19 weeks due
to concern for new right ventricular (RV) dilation and
tricuspid regurgitation after recent radiofrequency abla-
tion (RFA) for twin-reversal arterial perfusion (TRAP)
sequence. The pregnancy was a monochorionic diamni-
otic gestation. At 7-week gestation, twin B was found to
be acardiac and anencephalic consistent with TRAP. Fetal
echocardiogram for the pump twin at 17 weeks showed
cardiomegaly but a structurally normal heart with normal
valvar and ventricular function. RFA of the vascular sup-
ply to the acardiac twin was successfully performed at an
outside facility without acute complication. Peri-proce-
dural indomethacin was administered for three days as a
tocolytic.
Approximately ten days after the RFA was performed,
the patient was referred to our Fetal Care Center for fetal
echocardiography due to new RV dilation and tricuspid
regurgitation (TR) in the pump twin. Echocardiogram
showed moderate TR, RV hypertrophy and hypertension
with TR jet velocity indicating RV pressure ~80 mm Hg
plus the right atrial v-wave. Serial echocardiograms over
the remainder of gestation showed worsening (severe) tri-
cuspid regurgitation, continued severe RV hypertension as
well as progressive RV hypertrophy and dysfunction. No
patent ductus arteriosus (PDA) could be identified on the
initial or follow-up echocardiograms. A presumptive diag-
nosis of premature PDA closure related to peri-procedural
indomethacin was made. At the last fetal echocardiogram
performed at 32 weeks, there was severe tricuspid regurgi-
tation, severe RV hypertrophy and hypertension, mild-to-
moderate RV dysfunction and no pericardial effusion or
hydrops (Fig. 1).
The viable twin was delivered at 34 weeks via emer-
gent Cesarean section due to nonreassuring fetal heart
rate. Upon delivery, APGAR was eight at one and
5 min. Postnatal echocardiogram shortly after birth
showed: no PDA, severely dilated right atrium, severe
TR, severe RV hypertrophy and hypertension, and
mild-to-moderate RV dysfunction. Left heart structures
were normal. The neonate was administered 24 h of
nitric oxide and remained on supplemental oxygen via
nasal cannula. Oxygen saturations were ~80% due to
bidirectional patent foramen ovale flow (PFO). With
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supplemental oxygen over the first seven days of life,
oxygen saturations improved to ~93% and there was
marked improvement in the degree of RV hypertension.
The patient is now 3 years old and has undergone no
cardiac procedures. At the most recent follow-up,
growth and development are normal. The oxygen satu-
ration is now 98%. Echocardiogram shows moderate
TR with normal predicted RV pressure, borderline
dilated RV with normal function and no hypertrophy.
Discussion
Indomethacin is well established as an effective tocolytic
agent [1–3]. Indomethacin has a long track record in
prevention of spontaneous preterm labor and more
recently has been administered to prevent preterm labor
during several types of midgestation fetal interventional
procedures. Prior studies have reported that third-trime-
ster administration of indomethacin can lead to con-
striction of the ductus arteriosus that is generally
reversed by removing the drug [2, 4, 5]. Indomethacin
sensitivity is associated with gestational age as the inci-
dence of ductal constriction increases with increasing
gestational age. The risk of PDA restriction/closure with
indomethacin is generally thought to be low in early
second trimester [4, 5]. Current guidelines from the
American College of Obstetricians and Gynecologists
recommend an upper gestational age threshold of
32 weeks for tocolytic use of Indocin [6].
In this case, we present an 18-week fetus who devel-
oped irreversible PDA closure due to peri-procedural
indomethacin administration. The fetus developed severe
cardiac sequelae in utero due to PDA closure and resul-
tant severe RV pressure load. The sequelae included RV
hypertrophy and dysfunction as well as severe TR and
right atrial dilation. Fortunately, the fetus did not develop
frank RV failure or hydrops fetalis which can occur with
severely increased RV afterload.
In utero ~75% of RV output bypasses the high-
resistance pulmonary circulation through the patent duc-
tus arteriosus. With in utero PDA closure, the entire RV
output (~60% of combined cardiac output) is forced
through the high-resistance pulmonary circulation. This
obligatory increase in pulmonary blood flow combined
with the fixed high pulmonary vascular resistance leads to
a marked increase in RV afterload. This fetus manifested
typical consequences of increased RV afterload including
RV hypertrophy and systolic dysfunction, as well as TR,
and right atrial dilation due to TR and noncompliance of
the hypertrophied RV. In some cases, this cascade of right
heart dysfunction can lead to overt RV failure and
hydrops fetalis [7, 8]. Fortunately, this fetus did not
develop hydrops fetalis and was delivered at only mildly
preterm.
(A) (B)
(C) (D)
Figure 1. Fetal echocardiogram at 22-week gestation. (A) Four-chamber view showing severe right atrial dilation, dilated tricsupid valve, and
right ventricular hypertrophy. (B) Four-chamber view with color flow on the tricuspid valve showing severe tricuspid regurgitation. (C) Continuous-
wave Doppler of the tricuspid regurgitation jet showing severe right ventricular hypertension. Estimated right ventricular pressure is 88 mm Hg
plus the right atrial v-wave. (D) Doppler flow profile of the ductus venosus showing a-wave flow reversal.
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Following birth, the neonate did not require any cardiac
interventions. Normally, pulmonary vascular resistance
(PVR) decreases within the first days of life; however, in
this patient, it was delayed likely due to the increased pul-
monary blood flow through fetal life and resultant changes
in the pulmonary vasculature. In order to promote the pul-
monary artery relaxation and drop in PVR, inhaled nitric
oxide (iNO) and oxygen were administered for twenty-
four hours. With iNO and supplemental oxygen, clinical
and echocardiographic evidence of RV hypertension
improved quickly. Serial postnatal echocardiograms
showed normalization in RV pressure within the first two
weeks of life, followed by a gradual resolution of RV hyper-
trophy, and RV dysfunction over the first six months of
life. This case illustrates that it is imperative to monitor
patients with ductal constriction or closure throughout
gestation to ensure delivery prior to the onset of right heart
failure or hydrops fetalis. Postnatal management should
focus on therapies to reduce PVR which will improve right
heart hemodynamics and lead to less right-to-left PFO
shunting and cyanosis. Fetuses that can escape this neona-
tal period without extreme prematurity, hydrops, or RV
failure have good long-term prognosis [9, 10].
In conclusion, this case highlights that PDA restriction
or closure is a rare but a potentially severe complication
of second-trimester indomethacin use, despite prior
reports indicating that indomethacin is a safe tocolytic at
gestational age <32 weeks. In cases of premature PDA clo-
sure, serial echocardiograms are indicated to monitor the
severity of the right heart dysfunction and for develop-
ment of hydrops fetalis. Additionally, this case illustrates
the characteristic fetal cardiac manifestations of premature
PDA closure.
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